Meet DermaSensor: a non-invasive, AI-powered device that provides an immediate, objective result for skin cancer risk.
50% Off for the First 3 Months – Now $199/Month (Regularly $399 for Unlimited Users & Patients)
96% sensitivity for detecting all three common skin cancers ¹
Proprietary, FDA-cleared algorithm provides instant results
First FDA device cleared for primary care use
Founder of PT Family Medicine
“With integrating DermaSensor’s innovative technology into our practice, we can now offer enhanced skin cancer assessment capabilities right in our community, ensuring timely referrals for our patients.”
Skin cancer is a pervasive and underdiagnosed health concern in the United States, exacerbated by the inefficiencies within the healthcare system. Primary care physicians, who are on the frontline to appropriately treat and triage a host of conditions, have had a lack of adequate diagnostic aids to assess skin lesions. There is an unmet need for tools to improve identification of lesions requiring referral, which may otherwise lead to delayed or missed detection of skin cancer.
Reflects and records light from the lesion’s cellular and sub-cellular structures.
The built-in computer evaluates light patterns to help physicians assess skin lesions—including melanomas, squamous cell carcinoma, and basal cell carcinoma—for referral decisions.
Based on light scattering, DermaSensor recommends either “Monitor” or “Investigate Further”. The latter includes a 1–10 confidence score for malignancy likelihood.
Elastic Scattering Spectroscopy (ESS) is supported by 30+ clinical studies, showing results comparable to histopathology in analyzing cellular structure.
“As a dermatologist that trained PCPs at One Medical for years, I think this device will be transformational for PCPs correctly managing suspicious lesions.”
